TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04335006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carelizumab
Description: Participants receive SHR-1210 intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carelizumab
Description: Participants receive SHR-1210 intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: administered intravenously every 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: administered intravenously every 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: administered intravenously every 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: administered orally every 4-week cycle
Study: NCT02951377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise (MDT approach)
Description: Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)
Description: An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
Study: NCT01362660

Intervention type: OTHER
Intervention: Unintentional exposure in utero
Description: This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
Study: NCT03770637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon RTU
Description: Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).
Study: NCT00359151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
Study: NCT01576653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fungitell Assay in BAL
Description: Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fungitell Assay in BAL
Description: Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
Study: NCT03489174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Pregnancy Screening
Description: Pregnancy test will be administered once per month during weekly urine testing for drug levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care.
Study: NCT04849936

Intervention type: DIAGNOSTIC_TEST
Intervention: Testing Fecal Biomarkers In Comparison To Endoscopic Examination With Confocal Laser Endomicroscopy
Description: Patients, who were examined during a routine diagnostics, should submit an extra morning stool sample up to two weeks before or after the gastroscopy and/or coloscopy to generate the data of the fecal biomarker mentioned above.
Study: NCT04068259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBI-4547
Description: PBI-4547 tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study: NCT05210218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)
Description: The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: cellulose
Study: NCT01041352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laryngeal mask
Description: LMA Proseal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endotracheal tube
Description: Unomedical endotracheal tube
Study: NCT01561209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitryptiline
Description: Amitryptiline 5 mg before bedtime for 2 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill~1 before bedtime
Study: NCT02529813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given IV
Study: NCT02742623

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY 59-7939)
Description: Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
Study: NCT01581151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Ranibizumab
Description: 30 days between treatments
Study: NCT02548260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndactyly without compression
Description: three week relative immobilization by syndactyly

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Syndactyly with compression
Description: three week relative immobilization by syndactyly and compression

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid splint without compression
Description: three week rigid immobilization by splint

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rigid splint with compression
Description: three week rigid immobilization by splint and compression
Study: NCT00816686

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-16M18
Description: IV Infusion
Study: NCT01208441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gamma-secretase/Notch signalling pathway inhibitor RO4929097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: breast biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02108587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography
Description: Undergo optical coherence tomography
Study: NCT05635539

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet
Description: calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Analimentary detoxication (ANADETO) weight loss based on very-low-calorie-diet
Description: calorie restriction to 50-100 kcal/day with fat-free vegetables (tomatoes and cucumbers) with mandatory salt intake to 5-6 gr/day, hot water drinking 1000-1500 ml/day, walking at least 2,000 steps/day after normalized body temperature, and sexual self-restraint. The walking provided to promote of blood circulation and decrease in metabolic intoxication. The weight loss method lasted 14 days. Then the patients followed for 4-week a diet where they ate one meal a day without any food restriction.
Study: NCT02489123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01128894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: albiglutide
Description: albiglutide weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
Study: NCT02091050

Intervention type: OTHER
Group type: OTHER
Intervention: 2D HDR planning
Description: HDR planning using simple radiograph (2D)

Intervention type: OTHER
Group type: OTHER
Intervention: 3D HDR planning
Description: HDR planning using computed tomography (3D)
Study: NCT03958786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified Geriatric Evaluation
Description: * Questionnaires~* Self assessment questionnaires~* Mobility and balance tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: - Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12
Study: NCT00334724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home blood pressure measurement
Description: Blood pressure controlled based on home blood pressure measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office blood pressure measurement
Description: Blood pressure controlled based on office blood pressure measurement
Study: NCT04785235

Intervention type: PROCEDURE
Intervention: Non-Surgical Periodontal Therapy

Intervention type: PROCEDURE
Intervention: Non-Surgical Periodontal Therapy
Study: NCT02222051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: traditional chinese martial art meditative movement technique

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neck exercises
Description: group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
Study: NCT00153517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral versus vaginal metronidazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral versus vaginal metronidazole
Study: NCT03437278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ligelizumab
Description: Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ligelizumab
Description: Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg or 24 mg, high and low doses respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0 mg per 1 ml liquid injection once every 4 weeks.
Study: NCT01135550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose dexamethasone
Description: Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose dexamethasone
Description: Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.~If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
Study: NCT02070536

Intervention type: OTHER
Intervention: sRAGE
Study: NCT02439437

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Intervention
Description: Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
Study: NCT01477333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UT-15C SR
Description: Initiated at 0.125 mg BID, titrated as clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tyvaso Inhalation Solution
Description: Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
Study: NCT03133520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow oxygen therapy
Description: High-flow nasal oxygen \[HFNO\] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates \[of up to 60 L/min\] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
Study: NCT02843204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients received i.v. pembrolizumab (10 mg/kg) on day 1 of a 21-day cycle, until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
Study: NCT00066157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal estradiol
Description: 50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone
Description: 2.5mg tablet daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone
Description: 2.5mg tablet daily for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal placebo patch, changed every 3 days, for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal placebo patch, changed every 3 days, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily for 12 months
Study: NCT02963506

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Bimekizumab in different dosages.
Study: NCT02843204

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
Study: NCT00553956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy/Interpersonal Psychotherapy
Description: The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
Study: NCT00144651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA(Tocilizumab)
Description: 8mg/kg/4 weeks for 1 year
Study: NCT03136328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATOC
Description: The intervention is to administer 68Ga-DOTATOC PET/CT for detecting NET.
Study: NCT01228708

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active implementation of a guideline for chronic disease
Description: Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD
Study: NCT00874341

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and vegetable intervention
Description: Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit and vegetable intervention
Description: Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
Study: NCT03840239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin
Description: Drug: Capecitabine, Oxaliplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy to the primary tumor, regional lymph nodes and clinical target volume

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 'Local excision' or 'Intersphincter resection' or 'Total mesorectal excision' or other surgeries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Watch and wait strategy
Description: Watch and wait strategy recommendation and discussion for cCR patients
Study: NCT04876118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study: NCT01780974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipoic Acid plus Omega-3 Fatty Acids
Description: alpha lipoic acid (racemic) and fish oil concentrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules
Study: NCT00928239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sacropexy with mid vaginal attachment
Description: * supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacropexy with caudal vaginal attachment
Description: * supracervical hysterectomy for uterine prolapse~* exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior~* dissection up to ventrolateral part of the levator ani muscle~* Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder~* Two separate meshes, Gynemesh® (Johnson\&Johnson) a polypropylene mesh, for anterior and posterior compartment~* suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump~* placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex~* suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2